The Filing Desk

Kymera Therapeutics vs Voyager Therapeutics

Kymera Therapeutics KYMR · Voyager Therapeutics VYGR · Biotechnology

Voyager Therapeutics reported revenue of $40 million in fiscal 2025, about the same as Kymera Therapeutics' $39 million in fiscal 2025. Kymera Therapeutics' revenue fell 16.7% in its latest year, and Voyager Therapeutics' fell 49.5%. Kymera Therapeutics had an operating margin of -891.1%, against -326.6% at Voyager Therapeutics. Free cash flow was −$234 million at Kymera Therapeutics and −$135 million at Voyager Therapeutics.

Side by side

Kymera TherapeuticsVoyager Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$39M$40M
Revenue growth−16.7%−49.5%
Revenue growth a year, last 5 years2.9%−25.1%
Gross margin0.0%—
Operating margin−891.1%−326.6%
Net margin−794.0%−296.5%
Free cash flow−$234M−$135M
Free cash flow margin−597.6%−334.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count12.6%1.8%
Last close$119.39$1.61
P/E at the last close——
Insider trades, last 12 monthsbought $172.5 million, sold $461.2 millionsold $297,957
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Kymera TherapeuticsVoyager Therapeutics
Operating margin
Percent of revenue
Kymera TherapeuticsVoyager Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Kymera TherapeuticsVoyager Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Kymera Therapeutics and Voyager Therapeutics pages.